Positive Ph1 Results for AC Immune's NLRP3 Inflammasome Inhibitor

Positive Ph1 results for AC Immune's NLRP3 inflammasome inhibitor

AC Immune has announced positive interim results from its Ph 1 study of ACI-19764 – a NLRP3 inflammasome inhibitor targeting chronic inflammation.

AC Immune posts trial data for inflammatory drug (ACIU:NASDAQ)

AC Immune (ACIU) stock rises on initial data from a Phase 1 trial for its anti-inflammatory candidate ACI-19764. Read more here.

AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764

ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome Preliminary data showed ACI-19764 was safe and well tolerated across single and multiple ascending dose cohorts with confirmed CSF penetration Based on PK data the therapeutic dose is expected to be ≤10mg once daily To rapidly evaluate the anti-inflammatory activity of ACI-19764 (effect on hsCRP), […] The post AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhi…